Literature DB >> 26458093

Histopathology of melanocytic lesions in a family with an inherited BAP1 mutation.

Sally J O'Shea1, Angana Mitra2, Jennifer L Graham3, Ruth Charlton4, Julian Adlard5, Will Merchant3, Julia A Newton-Bishop1.   

Abstract

Entities:  

Keywords:  histopathology; melanocytic lesions; melanoma

Mesh:

Substances:

Year:  2015        PMID: 26458093      PMCID: PMC4819440          DOI: 10.1111/cup.12625

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


× No keyword cloud information.
We read with interest the report by Marusic et al.1 who expanded on the histopathological features of melanocytic neoplasms in a family with an inherited BAP1 mutation. Marusic et al.1 described the presence of nuclear pseudoinclusions and multinucleated melanocytes within five of six nevi from this family. The lesions were mainly intradermal, composed of large epithelioid melanocytes, and showed loss of BAP1 expression by immunohistochemistry. We report similar histopathological findings in melanocytic lesions excised from members of an English family in which a germline pathogenic BAP1 mutation has been identified. The proband was diagnosed with melanoma at 26 years of age that was clinically bland and pink in appearance. This was initially considered to be a melanocytic lesion of uncertain malignant potential (MELTUMP) but on further assessment, showed significant cytological atypia and lacked maturation and was therefore treated as a melanoma. The Breslow thickness was 2.4 mm and there was no evidence of ulceration. This patient later developed a melanoma in situ. He had multiple pink, bland nevi one of which subsequently changed and this was excised in view of his significant history. Histopathological examination showed an intradermal melanocytic neoplasm composed of epithelioid melanocytes with abundant cytoplasm, some of which contained multinucleated cells (Fig. 1A) and nuclear pseudoinclusions (Fig. 1B).
Figure 1

A) Histopathological findings (×20) show a predominantly intradermal melanocytic lesion. Multinucleated melanocytes can be clearly seen. B) High‐power view (×63) reveals a melanocytic lesion composed of multinucleated melanocytes. Nuclear pseudoinclusions are seen in some melanocytes. This lesion was considered to be a benign melanocytic nevus and resembled nevi described in other patients with a BAP1 mutation.

A) Histopathological findings (×20) show a predominantly intradermal melanocytic lesion. Multinucleated melanocytes can be clearly seen. B) High‐power view (×63) reveals a melanocytic lesion composed of multinucleated melanocytes. Nuclear pseudoinclusions are seen in some melanocytes. This lesion was considered to be a benign melanocytic nevus and resembled nevi described in other patients with a BAP1 mutation. The proband's maternal grandfather had occupational exposure to asbestos and had died of mesothelioma. His maternal uncle had a history of stage IIA melanoma, which later metastasized to a regional lymph node. Striking pleomorphism, multinucleated melanocytes and nuclear pseudoinclusions were readily identified in this nodal metastasis. The proband's maternal aunt, presented at 44  years of age with a history of a recalcitrant scalp lesion, which had been curetted twice elsewhere in the belief that this was a cyst. The curettings had not been sent for histopathological assessment. Following a further recurrence, approximately 18  months after onset, the lesion was partially excised by general surgeons. Histopathology revealed a malignant blue nevus‐like melanoma showing a highly cellular melanocytic tumor, at least 11 mm in thickness; composed of spindle cells and some dendritic‐like melanocytes. Nuclear pseudoinclusions were noted, although distributed more sparsely within this lesion. To our knowledge, there is only one other reported case of a 64‐year‐old female with a BAP1 germline mutation who had a malignant blue nevus‐like melanoma of the scalp.2 Our patient was also found to have a meningioma on computed tomography (CT) scanning. Following an invitation for screening, the proband's maternal cousin had a pink lesion excised, due to a history of change. This was diagnosed as a spitzoid tumor of uncertain malignant potential (STUMP). The tumor consisted of a lobulated, intradermal nodule composed of pleomorphic epithelioid melanocytes, flanked by a more diffuse melanocytic lesion with hyperchromatic nuclei (Fig. 2A). Nuclear pseudoinclusions were numerous within the nodular component (Fig. 2B).
Figure 2

A) Low‐power view (×2.5) shows an intradermal melanocytic neoplasm composed of a nodule flanked by a more diffuse melanocytic lesion. B) High‐power view (×60) demonstrates remarkable nuclear pseudoinclusions.

A) Low‐power view (×2.5) shows an intradermal melanocytic neoplasm composed of a nodule flanked by a more diffuse melanocytic lesion. B) High‐power view (×60) demonstrates remarkable nuclear pseudoinclusions. Atypical spitzoid tumors are known to occur in patients who have an inherited BAP1 mutation, the histopathology of which is usually quite striking in stark contrast to the bland clinical appearance of these lesions.3 Recognizing this pattern of clinical and histopathological presentation is key to identifying possible carriers of a BAP1 mutation, who have a cancer susceptibility syndrome, having a particular diathesis to cutaneous and uveal melanomas,3 meningiomas,4 mesotheliomas5 and renal cell cancers.1 Nuclear pseudoinclusions can be identified in several melanocytic tumors, including benign melanocytic nevi and even some melanomas.1 Although non‐specific, they appear to be a prominent feature of melanocytic lesions from patients with a germline BAP1 mutation.
  5 in total

1.  Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.

Authors:  Zlatko Marušić; Marija Buljan; Klaus J Busam
Journal:  J Cutan Pathol       Date:  2015-05-12       Impact factor: 1.587

2.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.

Authors:  Mohamed H Abdel-Rahman; Robert Pilarski; Colleen M Cebulla; James B Massengill; Benjamin N Christopher; Getachew Boru; Peter Hovland; Frederick H Davidorf
Journal:  J Med Genet       Date:  2011-09-22       Impact factor: 6.318

3.  Ambiguous melanocytic tumors with loss of 3p21.

Authors:  Iwei Yeh; Thaddeus W Mully; Thomas Wiesner; Swapna S Vemula; Sonia A Mirza; Alyssa J Sparatta; Timothy H McCalmont; Boris C Bastian; Philip E LeBoit
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

4.  BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.

Authors:  Michele Carbone; Laura Korb Ferris; Francine Baumann; Andrea Napolitano; Christopher A Lum; Erin G Flores; Giovanni Gaudino; Amy Powers; Peter Bryant-Greenwood; Thomas Krausz; Elizabeth Hyjek; Rachael Tate; Joseph Friedberg; Tracey Weigel; Harvey I Pass; Haining Yang
Journal:  J Transl Med       Date:  2012-08-30       Impact factor: 5.531

5.  Germline mutations in BAP1 predispose to melanocytic tumors.

Authors:  Thomas Wiesner; Anna C Obenauf; Rajmohan Murali; Isabella Fried; Klaus G Griewank; Peter Ulz; Christian Windpassinger; Werner Wackernagel; Shea Loy; Ingrid Wolf; Agnes Viale; Alex E Lash; Mono Pirun; Nicholas D Socci; Arno Rütten; Gabriele Palmedo; David Abramson; Kenneth Offit; Arthur Ott; Jürgen C Becker; Lorenzo Cerroni; Heinz Kutzner; Boris C Bastian; Michael R Speicher
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

  5 in total
  3 in total

1.  Novel insights into the BAP1-inactivated melanocytic tumor.

Authors:  Michele Donati; Petr Martinek; Petr Steiner; Petr Grossmann; Tomas Vanecek; Liubov Kastnerova; Isabel Kolm; Martina Baneckova; Pietro Donati; Irina Kletskaya; Antonina Kalmykova; Josef Feit; Petr Blasch; Diana Szilagyi; Alfonso Baldi; Paolo Persichetti; Anna Crescenzi; Michal Michal; Dmitry V Kazakov
Journal:  Mod Pathol       Date:  2021-12-02       Impact factor: 7.842

2.  A population-based analysis of germline BAP1 mutations in melanoma.

Authors:  Sally J O'Shea; Carla Daniela Robles-Espinoza; Lauren McLellan; Jeanine Harrigan; Xavier Jacq; James Hewinson; Vivek Iyer; Will Merchant; Faye Elliott; Mark Harland; D Timothy Bishop; Julia A Newton-Bishop; David J Adams
Journal:  Hum Mol Genet       Date:  2017-02-15       Impact factor: 6.150

Review 3.  Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.

Authors:  Michele Carbone; J William Harbour; James Brugarolas; Angela Bononi; Ian Pagano; Anwesha Dey; Thomas Krausz; Harvey I Pass; Haining Yang; Giovanni Gaudino
Journal:  Cancer Discov       Date:  2020-07-20       Impact factor: 38.272

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.